Sub menu

 

 

Guideline on clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy

We have adopted this International Scientific Guideline - EMEA/CPMP/555/95 Rev. 1.

Last updated

About this guideline

Overseas effective date:  1 October 2007

Replaces: CPMP/EWP/555/95 (adopted by TGA 1 May 2000)

Categories: Clinical efficacy and safety | Antineoplastic and immunomodulating agents

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Product types